The fructose-1.6-bisphosphatase 1 (FBP1) antibody is a critical tool for studying the role of FBP1. a rate-limiting enzyme in gluconeogenesis that catalyzes the hydrolysis of fructose-1.6-bisphosphate to fructose-6-phosphate. Primarily expressed in the liver and kidneys, FBP1 regulates glucose homeostasis by counterbalancing glycolytic pathways. Research interest in FBP1 has expanded due to its emerging roles beyond metabolism, including tumor suppression. Studies reveal that FBP1 downregulation or loss is linked to cancers like hepatocellular carcinoma and renal cell carcinoma, where its absence correlates with enhanced glycolysis (Warburg effect), proliferation, and metastasis. However, FBP1 exhibits context-dependent roles in cancer, acting as both a tumor suppressor and a potential promoter in specific contexts.
FBP1 antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to quantify protein expression, assess tissue localization, and explore molecular mechanisms in metabolic disorders (e.g., diabetes) and cancer. These antibodies must distinguish FBP1 from its isoform FBP2. which shares structural homology but has distinct tissue _expression (e.g., muscle). Validated FBP1 antibodies aid in clarifying its dual metabolic and non-metabolic functions, offering insights into disease pathways and therapeutic targeting. Recent studies also investigate FBP1's interplay with signaling pathways (e.g., mTOR, HIF), emphasizing its relevance in hypoxia responses and metabolic reprogramming.